Currently out of the existing stock ratings of Greg Harrison, 89 are a BUY (71.77%), 30 are a HOLD (24.19%), 5 are a SELL (4.03%).

Greg Harrison

Work Performance Price Targets & Ratings Chart

Analyst Greg Harrison, currently employed at BAML, carries an average stock price target met ratio of 60.54% that have a potential upside of 35.68% achieved within 148 days.

Greg Harrison’s has documented 244 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AGIO, Agios Pharm at 26-Dec-2025.

Wall Street Analyst Greg Harrison

Analyst best performing recommendations are on OMER (OMEROS).
The best stock recommendation documented was for AGIO (AGIOS PHARM) at 11/21/2025. The price target of $32 was fulfilled within 4 days with a profit of $13.49 (29.65%) receiving and performance score of 74.14.

Average potential price target upside

of $47.79 (14.58%) on UTHR (UNITED THERAPEUTICS).
of $43.88 (11.46%) on VRTX (VERTEX PHARMACEUTICALS).
of $42.15 (15.52%) on ALNY (ALNYLAM PHARMACEUTICALS).

ATHX Athersys NKTR Nektar Therapeutics RCKT Rocket Pharmaceuticals TVTX Travere Therapeutics AGIO Agios Pharm RDUS Schnitzer Steel Industries STOK Stoke Therapeutics OMER Omeros EDIT Editas Medicine NLTX Neoleukin Therapeutics LQDA Liquidia Technologies BBIO BridgeBio Pharma ISEE IVERIC bio BEAM Beam Therapeutics UTHR United Therapeutics NTLA Intellia Therapeutics SGMO Sangamo Therapeutics ALNY Alnylam Pharmaceuticals APLS Apellis Pharmaceuticals KROS Keros Therapeutics VRTX Vertex Pharmaceuticals IRON Disc Medicine ARCT Arcturus Therapeutics Holdings GERN Geron OCUL Ocular Therapeutix VERA Vera Therapeutics

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score